Radisson Hotel Narita
286-0221 Chiba Tomisato- shi Nakaei
650-35 Tokyo, Japan
Phone : 1 (702) 988 2320
Toll Free: 1800–883-8082
Email: cardiology@magnusmeetings.com
October 24-25, 2019 | Tokyo, Japan

Naresh Ranjith

Keynote Speaker at Cardiovascular Conference- Naresh Ranjith
Naresh Ranjith
University of KwaZulu-Natal, South Africa
Title : What is new in heart failure?

Abstract:

Heart failure is a common clinical syndrome that is characterized by frequent hospitalization and increased mortality.  The mortality rate after one year is between 20 to 30% and increases to about 50% after 5 years, despite improvements in pharmacotherapy and device therapy.

Consequently, the worlds attention has shifted to research in the field of heart failure with numerous ongoing clinical trials undertaken in heart failure to try and reduce this global burden.  The definition of heart failure was changed by the European Society of Cardiology and now focuses on new ejection fraction definitions with clear diagnostic criteria. 

Several new drugs have been included in Heart Failure Guidelines such as the Sacuitril/Valsartan compound which is the first in a class of Angiotensin Receptor Neprilysin Inhibitor (ARNI). In addition, iron therapy, the role of Soluble Guanylate Cyclase (sGC) compounds and Sodium-glucose Cotransporter-2 (SGLT2) inhibitors in heart failure will be discussed.

Biography:

Prof N Ranjith Currently in private practice at the Cardiovascular Centre in Merebank and at City Hospital JMH holdings [Director of the Heart Failure and Cardiac Centre]. Part time at Nelson R Mandela School of Medicine, Professor in Cardiology-teach both under and post graduate students. Fellow of the European Society of Cardiology and European Society of Heart Failure.Secretary of the South African Heart Failure Society and a member of the steering committee of the South African Hypertension Society. On numerous advisory boards and editorial boards of many international journals and a member of various international cardiac societies Involved in research both nationally and internationally in the field of cardiology and have published over a 100 papers in this area. Now concentrating on preventing heart diseases both at a primary and secondary level in our committee.